<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383197</url>
  </required_header>
  <id_info>
    <org_study_id>H-19008233</org_study_id>
    <nct_id>NCT04383197</nct_id>
  </id_info>
  <brief_title>Exercise and GLP-1 RA on Insulin Secretion</brief_title>
  <acronym>EXISECRET</acronym>
  <official_title>Effects of 12 Weeks of Endurance Exercise Training Alone or in Combination With Glucagon Like Peptide 1 Receptor Agonist (GLP-1 RA) Treatment on Insulin Secretory Capacity in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of endurance exercise on insulin
      secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor
      agonist semaglutide, in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of endurance exercise alone or in addition to treatment with glucagon-like-
      peptide receptor agonists on insulin secretory capacity, will be determined in patients with
      type 2 diabetes.

      Included patients will be randomized to either 12 weeks of endurance exercise training 3
      times a week or therapeutical treatment with semaglutide for 3 months followed by 12 weeks of
      endurance exercise training 3 times a week. Insulin secretory capacity will be determined by
      hyperglycemic clamp method before and after.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>Change from baseline insulin secretion after Exercise intervention(12 weeks).</time_frame>
    <description>By hyperglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>Change from baseline insulin secretion after 3 months of therapeutic semaglutide treatment</time_frame>
    <description>By hyperglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>Change from baseline insulin secretion after 3 months of combined exercise and therapeutic semaglutide treatment</time_frame>
    <description>By hyperglycemic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment</time_frame>
    <description>By Oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>Before and after (2 days) Exercise intervention(12 weeks). Before and after 3 months of therapeutic semaglutide treatment</time_frame>
    <description>Derived from hyperglycemic clamp and HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma bone markers</measure>
    <time_frame>Before and after (2 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment</time_frame>
    <description>Changes in baseline CTX, PNIP, Osteocalcin and alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose homeostasis</measure>
    <time_frame>Before and after (2 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment</time_frame>
    <description>Changes in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory fitness</measure>
    <time_frame>Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment</time_frame>
    <description>Changes in maximal oxygen uptake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment</time_frame>
    <description>By DXA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Semaglutide treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months of therapeutic semaglutide treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide and Endurance exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of endurance exercise concomitant to semaglutide treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endurance exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of endurance exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Endurance exercise training</intervention_name>
    <description>Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week</description>
    <arm_group_label>Endurance exercise</arm_group_label>
    <arm_group_label>Semaglutide and Endurance exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>3 months of therapeutic treatment with semaglutide</description>
    <arm_group_label>Semaglutide and Endurance exercise</arm_group_label>
    <arm_group_label>Semaglutide treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes

          -  BMI 28-35

          -  Moderately preserved insulin secretory capacity (determined by glucagon test)

        Exclusion Criteria:

          -  Insulin treatment

          -  Hypertension grade 3

          -  Heart disease

          -  Medical history with pancreatitis

          -  Diagnosed with neuropathy

          -  Excessive alcohol consumption

          -  Any condition that would interfere with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arthur Ingersen, MD</last_name>
    <phone>+45 60172697</phone>
    <email>hansai@sund.ku.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xlab, Center for Healthy Aging, Department of Biomedical Sciences, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Ingersen, MD</last_name>
      <phone>+45 60 17 26 97</phone>
      <email>hansai@sund.ku.dk</email>
    </contact>
    <investigator>
      <last_name>Flemming Dela, MD, DMsci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur Ingersen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Flemming Dela</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Insulin secretion</keyword>
  <keyword>Beta cell function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>yet to be decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

